Market Cap 2.18B
Revenue (ttm) 1.90B
Net Income (ttm) 235.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 12.37%
Debt to Equity Ratio 0.84
Volume 8,323,600
Avg Vol 10,776,328
Day's Range N/A - N/A
Shares Out 97.71M
Stochastic %K 87%
Beta 0.51
Analysts Sell
Price Target $23.88

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 274 4000
Address:
215 First Street, Suite 415, Cambridge, United States
MMillionaireWookie
MMillionaireWookie Oct. 4 at 11:03 PM
0 · Reply
BrittonHickman
BrittonHickman Oct. 4 at 10:52 PM
$SRPT as a 100% portfolio holder of srpt, I am ready.
0 · Reply
Plowmaster
Plowmaster Oct. 4 at 10:35 PM
$SRPT look forward to the clinical data next week starting an hour before market opens on Wednesday! Could be a very interesting week!
1 · Reply
heyupikachu1821
heyupikachu1821 Oct. 4 at 10:20 PM
$SRPT bullish on this stock, but also skeptical about the 25% rise over the past week. or at least the idea that it will get back to the $30’s before substantial news. would love to see FDA clearance, new data related to safety, EMA approval… anyone claiming this stock is gonna be at $70 in the next week is just pumping on air. a jump to $70 without news would realistically be a bull trap to allow big investors a decent exit point before crashing back down could it make it get back to $30 and maintain a position? possibly. but I’d still like to see some sort of development to validate the rise Until then, I’m cautiously optimistic short term, bullish longterm
1 · Reply
Shoco73
Shoco73 Oct. 4 at 9:31 PM
$SRPT LGMD2E Phase 3 results represent Sarepta’s first diversification beyond Duchenne into a $300-500M market, with BLA filing expected H2 2025. Bottom Line With Duchenne gene therapy racing toward $8.19B by 2030 and Pfizer competing, this week determines whether Sarepta solves its safety crisis while launching new franchises or faces strategic headwinds ahead
1 · Reply
Shoco73
Shoco73 Oct. 4 at 9:31 PM
$SRPT Sarepta’s Critical Week at WMS 2025 Sarepta faces a make-or-break moment at Vienna’s World Muscle Society Congress (October 7-11), with presentations that could determine its gene therapy franchise’s future. The Liver Crisis Solution (Thursday 2:00 PM) After two ELEVIDYS-related deaths in July 2025 triggered 36% workforce cuts and slashed guidance to $2.3-2.6B, Thursday’s sirolimus study is existential. This independent research tests whether prophylactic immunosuppression can prevent the life-threatening liver injury plaguing AAV gene therapy. ELEVIDYS generated $375M in Q1 alone positive sirolimus data restores growth trajectory; negative results raise peak sales questions. Beyond Safety Monday’s cardiac outcomes and multi-year efficacy data must prove ELEVIDYS delivers durable benefit worth $3M. Data in 3-4 year-olds could expand the market 25-30% below current 4+ age indication. Pipeline Validation (Thursday 2:00 PM)
0 · Reply
John62
John62 Oct. 4 at 8:53 PM
$SRPT I believe there will be at least one more dip down to take out stop losses plus few days of consolidation and then it’ll push through $23-25 area w high vol to close the gap at $35 . I’ll be ready to buy any big dip . Will obviously depend on the news / catalysts as well but my hunch is that it gets to $35-40 area within next couple weeks . Barring any bad news. $SPY $XBI $LABU
1 · Reply
Universaal
Universaal Oct. 4 at 8:11 PM
$SRPT pretty sure this will open $23 plus on Monday.. I would like to see cpak and broke millionaire’s current status..
0 · Reply
Universaal
Universaal Oct. 4 at 5:52 PM
$SRPT upcoming presentation schedule
2 · Reply
jchassin3311
jchassin3311 Oct. 4 at 5:25 PM
$SRPT presentations this weekend will send this higher on Monday!!!!
1 · Reply
Latest News on SRPT
mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 5 weeks ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA


Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 12:12 PM EDT - 6 weeks ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic


Opinion | On Sarepta, a Welcome FDA Reversal

Jul 29, 2025, 5:48 PM EDT - 2 months ago

Opinion | On Sarepta, a Welcome FDA Reversal


SRPT Rallies on FDA Green Light: A New Bottom for the Stock?

Jul 29, 2025, 2:06 PM EDT - 2 months ago

SRPT Rallies on FDA Green Light: A New Bottom for the Stock?


Sarepta: SRPT Stock To $40?

Jul 29, 2025, 9:00 AM EDT - 2 months ago

Sarepta: SRPT Stock To $40?


Sarepta Stock Just Soared 45%. Here's Why.

Jul 29, 2025, 5:01 AM EDT - 2 months ago

Sarepta Stock Just Soared 45%. Here's Why.


Sarepta Therapeutics: Beaten Down, But Not Out

Jul 28, 2025, 4:17 AM EDT - 2 months ago

Sarepta Therapeutics: Beaten Down, But Not Out


Opinion | The Sarepta Mugging and Drug Innovation

Jul 27, 2025, 1:37 PM EDT - 2 months ago

Opinion | The Sarepta Mugging and Drug Innovation


Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Jul 25, 2025, 7:51 PM EDT - 2 months ago

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS


MMillionaireWookie
MMillionaireWookie Oct. 4 at 11:03 PM
0 · Reply
BrittonHickman
BrittonHickman Oct. 4 at 10:52 PM
$SRPT as a 100% portfolio holder of srpt, I am ready.
0 · Reply
Plowmaster
Plowmaster Oct. 4 at 10:35 PM
$SRPT look forward to the clinical data next week starting an hour before market opens on Wednesday! Could be a very interesting week!
1 · Reply
heyupikachu1821
heyupikachu1821 Oct. 4 at 10:20 PM
$SRPT bullish on this stock, but also skeptical about the 25% rise over the past week. or at least the idea that it will get back to the $30’s before substantial news. would love to see FDA clearance, new data related to safety, EMA approval… anyone claiming this stock is gonna be at $70 in the next week is just pumping on air. a jump to $70 without news would realistically be a bull trap to allow big investors a decent exit point before crashing back down could it make it get back to $30 and maintain a position? possibly. but I’d still like to see some sort of development to validate the rise Until then, I’m cautiously optimistic short term, bullish longterm
1 · Reply
Shoco73
Shoco73 Oct. 4 at 9:31 PM
$SRPT LGMD2E Phase 3 results represent Sarepta’s first diversification beyond Duchenne into a $300-500M market, with BLA filing expected H2 2025. Bottom Line With Duchenne gene therapy racing toward $8.19B by 2030 and Pfizer competing, this week determines whether Sarepta solves its safety crisis while launching new franchises or faces strategic headwinds ahead
1 · Reply
Shoco73
Shoco73 Oct. 4 at 9:31 PM
$SRPT Sarepta’s Critical Week at WMS 2025 Sarepta faces a make-or-break moment at Vienna’s World Muscle Society Congress (October 7-11), with presentations that could determine its gene therapy franchise’s future. The Liver Crisis Solution (Thursday 2:00 PM) After two ELEVIDYS-related deaths in July 2025 triggered 36% workforce cuts and slashed guidance to $2.3-2.6B, Thursday’s sirolimus study is existential. This independent research tests whether prophylactic immunosuppression can prevent the life-threatening liver injury plaguing AAV gene therapy. ELEVIDYS generated $375M in Q1 alone positive sirolimus data restores growth trajectory; negative results raise peak sales questions. Beyond Safety Monday’s cardiac outcomes and multi-year efficacy data must prove ELEVIDYS delivers durable benefit worth $3M. Data in 3-4 year-olds could expand the market 25-30% below current 4+ age indication. Pipeline Validation (Thursday 2:00 PM)
0 · Reply
John62
John62 Oct. 4 at 8:53 PM
$SRPT I believe there will be at least one more dip down to take out stop losses plus few days of consolidation and then it’ll push through $23-25 area w high vol to close the gap at $35 . I’ll be ready to buy any big dip . Will obviously depend on the news / catalysts as well but my hunch is that it gets to $35-40 area within next couple weeks . Barring any bad news. $SPY $XBI $LABU
1 · Reply
Universaal
Universaal Oct. 4 at 8:11 PM
$SRPT pretty sure this will open $23 plus on Monday.. I would like to see cpak and broke millionaire’s current status..
0 · Reply
Universaal
Universaal Oct. 4 at 5:52 PM
$SRPT upcoming presentation schedule
2 · Reply
jchassin3311
jchassin3311 Oct. 4 at 5:25 PM
$SRPT presentations this weekend will send this higher on Monday!!!!
1 · Reply
Stocktwit1993
Stocktwit1993 Oct. 4 at 4:29 PM
$SRPT could this see $75 by year’s end?
7 · Reply
Universaal
Universaal Oct. 4 at 4:23 PM
$SRPT this came in August -25 just sharing
0 · Reply
_eric_
_eric_ Oct. 4 at 3:50 PM
$SRPT Imagine if Douglas S. Ingram be like this next week at WMS in Austria and drop PR bomb all week. Honestly its more a want than reality lol
0 · Reply
KillerTrader
KillerTrader Oct. 4 at 1:37 PM
$SRPT AT Daily chart
1 · Reply
Nettrunner1
Nettrunner1 Oct. 4 at 1:17 PM
$SRPT The Current Share price represents a $2.3 B mkt cap( 104M shares outstanding.) The pipeline ( SiRNA franchise & Arrowhead) are seeing $O value @ Current stock price. A positive readout can reignite speculation of $2+Billion revenue by 2027 from SiRNA Alone. Filling the Gap back to $37 is highly conservative Given today’s Revenue & cashflow. A Massive Short squeeze is also Unfolding given SRPT’s Ability to Repay Outstanding Convert debt thru projected cashflow. $700 M of the $1.2B convert debt due in 2027 was refinanced… The Remaining $500 M will be repaid in cash. The 20M share short position was Anchored ( hedged) against The anticipated Issuance of shares from the 2027 convert. Buckle your seatbelt ! MELT UP MEME Stock Squeeze Inbound.
2 · Reply
Nettrunner1
Nettrunner1 Oct. 4 at 1:17 PM
$SRPT The Drop from $36 ( Down from $120+)WAS driven by fears of a total loss of Elividys Revenue . We Now have a path back to full Elividys availability! Without “ non ambulatory “ revenue SRPT was Still generating Significant EPS( see recent co. guidance & cost savings associated with restructuring) The CHAOS surrounding Elividys withdrawal & return to Mkt forced Mgmt to eliminate wasteful spending & underperforming Pipeline investments. YOU ARE WITNESSING ONE OF THE MOST DRAMATIC REVERSALS OF BOTH FUNDAMENTALS & INVESTOR PSYCHOLOGY! From A Total loss of Elividys Revenue ($384M/Q at its peak to potentially 0 & Bankruptcy) SRPT revenue without Elividys ( Exondys,Vyondys & Amondys) will contribute approximately $800 M in 2025.. SRPT initially Guided for $2.9-3.1 B in 2025 Revenue & significant Profitability. In may guidance was Revised down to $2.3-2.5B to reflect Elividys Non ambulatory Withdrawal Continued
0 · Reply
Universaal
Universaal Oct. 4 at 11:59 AM
$SRPT closing above $22 has not happened since 6/16 and we got above average volume last two days. Anyone buying more on Monday?
2 · Reply
Bezhadimmu
Bezhadimmu Oct. 4 at 11:54 AM
$SRPT 200 dollar stock in 12 months.
0 · Reply
Thaigrlsrk
Thaigrlsrk Oct. 4 at 9:53 AM
$SRPT Based on what we have seen in the first four kids ( 5 years) the P values for embark 3 year kids will only get stronger over time. NH kids go downhill fast after 10 years old.
0 · Reply
Thaigrlsrk
Thaigrlsrk Oct. 4 at 9:38 AM
$SRPT 3 year embark pooled data. NSAA scvores and timed tests, all + with good P values: In english the shit weorks good over three years. https://investorrelations.sarepta.com/static-files/53ab5696-9459-4bf1-975c-68b69e3d2501
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 7:54 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SRPT Current Share Price: $22.64 Contracts: $SRPT January 15, 2027 $25 Calls Scale in: $8.54- $10.43 Scale out: $13.28-$17.07 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MarketQQueen
MarketQQueen Oct. 4 at 6:13 AM
$SRPT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.businesswire.com/news/home/20250930708580/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
0 · Reply